[HTML][HTML] Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): a randomized controlled trial
JA Singh, L Fraenkel, C Green, GS Alarcón… - PLoS …, 2019 - journals.plos.org
Background Treatment decision-making regarding immunosuppressive therapy is
challenging for individuals with lupus. We assessed the effectiveness of a decision aid for …
challenging for individuals with lupus. We assessed the effectiveness of a decision aid for …
[HTML][HTML] Development and content validity of the lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure …
AD Askanase, RP Daly, M Okado, K Neville… - Health and Quality of …, 2019 - Springer
Abstract Background/purpose The LFA REAL™ is a measurement system for evaluating
lupus disease activity from both clinician and patient perspectives. Patients' viewpoints are …
lupus disease activity from both clinician and patient perspectives. Patients' viewpoints are …
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment …
K Tse, S Sangodkar, L Bloch, K Arntsen… - Lupus Science & …, 2021 - lupus.bmj.com
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global
consensus effort to identify, prioritise and address top barriers in lupus impacting diagnosis …
consensus effort to identify, prioritise and address top barriers in lupus impacting diagnosis …
Comparison of the Lupus Foundation of America–Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical …
AD Askanase, SC Nguyen, K Costenbader… - Arthritis care & …, 2018 - Wiley Online Library
Objective Lupus disease measures such as the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index are …
Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index are …
The Spectrum of health domains important to lupus patients: early development of a disease activity patient reported outcome
AD Askanase, S Nguyen, K Neville… - Bulletin of the NYU …, 2019 - search.proquest.com
An increasingly accepted complement to the physician's evaluation of disease are reports
that come directly from patients in the form of patient-reported outcomes (PROs), which can …
that come directly from patients in the form of patient-reported outcomes (PROs), which can …
Establishing consensus understanding of the barriers to drug development in lupus
Y Peña, K Tse, LM Hanrahan, A de Bruin… - … Innovation & Regulatory …, 2020 - Springer
Objective Due to the extreme heterogeneity of lupus and the lack of consensus among
stakeholders, pharmaceutical and biotechnology companies have had limited success in …
stakeholders, pharmaceutical and biotechnology companies have had limited success in …
[CITATION][C] The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and …
A Askanase, T Kapoor… - ARTHRITIS & …, 2015 - … ST, HOBOKEN 07030-5774, NJ USA
[CITATION][C] The Real life with lupus study: developing a patient reported outcome measure for use in clinical trials and clinical care
RP Daly, S Gilman, JT Merrill… - ARTHRITIS & …, 2014 - … ST, HOBOKEN 07030-5774, NJ USA
[CITATION][C] Impact Of Baseline Disease Severity and Treatments On Outcomes In Clinical Trials Of SLE: Results From The Soccit Program
KC Kalunian, M Kim… - ARTHRITIS …, 2013 - … ST, HOBOKEN 07030-5774, NJ USA
[CITATION][C] Initial Results for the LFA Collective Data Analysis Initiative (LFA CDAI): How Do Subjects From Lupus Clinical Trials Randomized to Standard of Care …
KC Kalunian, M Kim… - ARTHRITIS …, 2011 - … , 350 MAIN ST, MALDEN 02148, MA …